Nerviano Medical Sciences

Discovery and development of new oncology drugs

Slider

Nerviano Medical Sciences

Discovery and development of new oncology drugs

$

SCROLL

$

SCROLL

About us

Nerviano Medical Sciences S.r.l is focused on discovery and clinical development of small molecule NCEs for oncology. The company takes innovative approaches on novel mechanisms of action and drug targets to bring first- and best-in-class personalized medicines to cancer patients.

Our current pipeline consists of NCEs, which all originate from our well validated oncology drug discovery platform that span from early preclinical to clinical stage projects and which are being developed both in house and with partners.

Nerviano Medical Sciences S.r.l combines the flexibility of a biotech with the quality of a big pharma. Here, an experienced management team leads a highly skilled staff of professionals with global vision and a broad range of expertise in research, drug discovery and clinical development. We cover the whole range of additional aspects of drug development through the NMS Group affiliate companies, Accelera (AdMet) and NerPharma (manufacturing).

A key strength is our industrially renowned kinase inhibitor drug discovery platform which comprises an ever evolving chemical collection with broad intellectual property coverage, discovery know-how and technologies which enabled us to out-license IP rights on recently approved innovative medicines such as encorafenib and entrectinib. Moreover, we are also developing a proprietary payload platform for generation of novel Antibody-Drug Conjugates (ADCs).

We collaborate with academia and clinical investigators as well as with industrial partners worldwide to advance our programs from early discovery to clinical development of new drugs. We seek further strategic collaborations to develop and commercialize our products in different territories as well as in-licensing opportunies of promising assets for clinical development.

READ OUR STORY

 Research

Our daily commitment

Research is the driving engine of our Company, with a longstanding experience in R&D and a proven track record of being able to perform innovative research and to bring molecules into clinical development up to registration.

Our research addresses different targets in key biological areas and molecular mechanisms that are crucial for onset and progression of diverse cancer types.

Our projects are supported by our scientific platforms, including the Kinase Platform and the ADC platform, that leverage our long standing expertise and technology approaches to generate economy of scale, allowing us to manage a broad project portfolio.

Clinical programs

We are exploiting our core Discovery engine to constantly develop new molecular entities with potential for “first in class” and “best in class”.

Our projects target a broad number of solid tumors and haematological indications, with a focus on biomarker selected patient populations. We are developing projects in house into clinical development in order to accelerate the clinical benefit for our patients.

DISCOVER MORE

 Pipeline

Our pipeline includes outlicensed molecules in advanced clinical stage or already registered, as well as a broad portfolio of molecules at preclinical and clinical stage that are being developed by Nerviano Medical Sciences in different indications.

DISCOVER MORE

Latest News & Events

Nerviano Medical Sciences received European Medicines Agency (EMA) Orphan Drug Designation for its next-generation FLT3 inhibitor NMS-03592088 for treatment of Acute Myeloid Leukemia

Nerviano Medical Sciences S.r.l. (NMS) announced that European Commission has granted Orphan Drug Designation (ODD) for NMS-03592088 for the treatment of Acute Myeloid Leukemia (AML), just a few weeks after the US Food and Drug Administration (FDA) approval.

(Click the title for the complete article)

New European Patent Office study: NMS srl top applicant in Italy during the 2002-2021 period

Nerviano, 1 February 2024     The new study “Patents and Innovation against Cancer”, just released today by the European Patent Office (EPO), reports Italy among top European nations in innovation to fight cancer. In the past 20 years close to 2 000 international patent families (IPFs) have been registered by Italian companies and research facilities. Among them, Nerviano Medical Sciences stands out as the top applicant during the 2002-2021 period.

(Click the title for the complete article)

Latest Events

Latest News

Careers

 Need more information?

Latest Events

Latest News

Careers

 Need more information?

 

Welcome and Check out our new motion picture!

WATCH OUR VIDEO